XW013TB
Introduction Subcutaneous Tissue to New Technology Group 11 with Rozanolixizumab-noli Monoclonal Antibody, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 1 Subcutaneous Tissue |
| Approach | 3 Percutaneous |
| Device | T Rozanolixizumab-noli Monoclonal Antibody |
| Qualifier | B New Technology Group 11 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Subcutaneous Tissue
Subcutaneous tissue is the fatty layer beneath the dermis that houses blood vessels, nerve endings, and connective tissue, and it serves as a common depot for sustained-release or systemically absorbed substances. Introduction procedures coded here under New Technology involve placing a novel agent into this layer specifically, distinguishing it from superficial skin application or injection into deeper muscle. Because subcutaneous tissue has variable thickness and vascularity depending on body location, absorption characteristics of the introduced substance can differ by site, which may influence dosing and monitoring. This code applies when the substance itself represents an advanced or newly approved technology, such as a novel biologic, rather than a conventional medication already captured under standard Administration section codes.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Rozanolixizumab-noli Monoclonal Antibody
Rozanolixizumab-noli is a monoclonal antibody that inhibits the neonatal Fc receptor, reducing circulating levels of pathogenic IgG autoantibodies, and is used in generalized myasthenia gravis to lessen autoimmune-mediated neuromuscular symptoms. Its FcRn-blocking mechanism differs from the cytokine-receptor blockade of satralizumab or the interleukin-36 receptor blockade of spesolimab, distinguishing its role among the autoimmune-indicated monoclonal antibodies in this list.
Qualifier: New Technology Group 11
This qualifier designates Group 11, the most recent cohort at the time of its introduction, grouping technologies newly approved for New Technology section reporting in that fiscal year. Like every group value in this axis, it functions as an administrative marker rather than a description of the clinical intervention, which is captured elsewhere in the code. Its main point of confusion is with Group 10, the immediately preceding annual release.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.